Advantage Alpha Capital Partners LP trimmed its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 40.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,947 shares of the company's stock after selling 9,371 shares during the period. Advantage Alpha Capital Partners LP's holdings in Alkermes were worth $401,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. raised its stake in shares of Alkermes by 6.5% during the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock valued at $99,242,000 after purchasing an additional 209,740 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Alkermes by 365.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock valued at $52,704,000 after buying an additional 1,478,422 shares during the period. Principal Financial Group Inc. raised its position in shares of Alkermes by 2.5% during the 4th quarter. Principal Financial Group Inc. now owns 899,764 shares of the company's stock worth $25,877,000 after buying an additional 21,821 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Alkermes in the 3rd quarter worth approximately $16,126,000. Finally, Rhumbline Advisers increased its stake in shares of Alkermes by 0.4% during the fourth quarter. Rhumbline Advisers now owns 464,714 shares of the company's stock valued at $13,365,000 after acquiring an additional 1,683 shares during the period. Institutional investors own 95.21% of the company's stock.
Alkermes Stock Down 1.0 %
Shares of Alkermes stock traded down $0.32 on Friday, hitting $33.21. 922,403 shares of the company traded hands, compared to its average volume of 1,751,921. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The company has a 50-day moving average price of $33.45 and a 200 day moving average price of $30.26. The company has a market cap of $5.40 billion, a PE ratio of 15.30, a PEG ratio of 2.20 and a beta of 0.62.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on ALKS shares. Deutsche Bank Aktiengesellschaft increased their price target on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research note on Thursday. UBS Group upgraded shares of Alkermes from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. HC Wainwright reiterated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. Finally, Royal Bank of Canada started coverage on Alkermes in a report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price target on the stock. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.38.
Check Out Our Latest Report on ALKS
Insider Activity at Alkermes
In other news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares in the company, valued at $2,056,298.75. This represents a 71.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.89% of the company's stock.
Alkermes Company Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
